NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-OD-18-191 from the NIH Guide for Grants and Contracts
Notice NOT-OD-18-190 from the NIH Guide for Grants and Contracts
Notice NOT-NS-18-072 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-AI-18-023 from the NIH Guide for Grants and Contracts. This initiative will support research to determine the roles and interactions of immune cells at the maternal-fetal interface throughout pregnancy, including mechanisms of responses to vaccination and infection that protect the fetus and that may influence fetal immune system development.
Notice NOT-AI-18-040 from the NIH Guide for Grants and Contracts
Notice NOT-NS-18-058 from the NIH Guide for Grants and Contracts
Notice NOT-NS-18-057 from the NIH Guide for Grants and Contracts
Notice NOT-NS-18-069 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-18-828 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages applications for investigator-initiated early phase clinical trials of natural products (i.e., botanicals, dietary supplements, and probiotics), which have a strong scientific premise to justify further clinical testing. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support decisions about further development or testing of the natural product. This FOA will provide up to 3 years support for studies to replicate the impact of the natural product on the biological signature(s) when used by humans and assess whether there is an association between the degree of the impact on the biological signature and functional or clinical outcomes in a patient population. Applications can design studies to determine how to optimize the impact of the natural product on the biological signature by (1) optimizing the delivery of the natural product by dose or formulation; (2) combine the natural product with another treatment approach that is known to impact the same biological signature; or (3) study the impact of the natural product in a target population that is more responsive. Clinical trials submitted under this FOA are expected to be hypothesis based, milestone-driven, and directly related to the research priorities and mission of NCCIH. This R33 funding mechanism is intended to accelerate the translation of emerging basic science findings about natural products into early stage clinical testing to determine whether continued clinical research is warranted. This FOA will not support efficacy or effectiveness trials, nor will it support trials to test natural products for the treatment or prevention of cancer.
Funding Opportunity PAR-18-829 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages applications for investigator-initiated early phase clinical trials of natural products (i.e., botanicals, dietary supplements, and probiotics), which have a strong scientific premise to justify further clinical testing. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support decisions about further development or testing of the natural product. This FOA will provide up to two years (R61 phase) of support for milestone-driven testing of bioavailability, pharmacokinetics, and assessment of the natural products effect (i.e., measure of mechanism of action) when used by humans on a biological signature(s). If milestones in the R61 phase are achieved, up to 3 years of additional support (R33 phase) may be awarded to replicate the impact of the natural product on the biological signature(s) when used by humans and assess whether there is an association between the degree of the impact on the biological signature and functional or clinical outcomes in a patient population. Applications can design R33 studies to determine how to optimize the impact of the natural product on the biological signature by (1) optimizing the delivery of the natural product by dose or formulation; (2) combine the natural product with another treatment approach that is known to impact the same biological signature; or (3) study the impact of the natural product in a target population that is more responsive. Clinical trials submitted under this FOA are expected to be hypothesis based, milestone-driven, and directly related to the research priorities and mission of NCCIH. This R61/R33 funding mechanism is intended to accelerate the translation of emerging basic science findings about natural products into early-stage clinical testing to determine whether continued clinical research is warranted. This FOA will not support efficacy or effecti
Funding Opportunity RFA-CA-18-015 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits applications from institutions/organizations to participate as "Research Bases" for the National Cancer Institute (NCI)-supported Community Oncology Research Program (NCORP). NCOR P is a community-based research network that: Designs and conducts clinical trials and other human subject studies for adults and children in cancer prevention, control, screening, and care delivery, as well as quality-of-life studies embedded within treatment trials; Incorporates unique research needs of diverse populations such as, adolescents and young adults (AYAs), and the elderly; racial and ethnic minorities; sexual and gender minorities; and rural residents into studies and takes steps to enhance participation of these groups; Enhances patient and provider access to treatment and imaging trials conducted under the National Clinical Trials Network (NCTN); Integrates cancer disparities research within the community network. NCORP consists of three components each with its own FOA: NCORP Research Bases (covered by this FOA); NCORP Community Sites; and NCORP Minority/Underserved Community Sites. The NCORP Research Bases will design and conduct cancer clinical trials and care delivery research studies as well as manage and analyze the data and report the research results.
Funding Opportunity RFA-CA-18-016 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits applications from institutions/organizations to participate as "Community Sites" for the National Cancer Institute (NCI)-supported Community Oncology Research Program (NCORP). NCOR P is a community-based research network that: Designs and conducts clinical trials and other human subject studies for adults and children in cancer control, prevention, screening, and care delivery, as well as quality-of-life studies embedded within treatment trials; Incorporates the needs of diverse populations such as children, adolescents and young adults (AYAs), and the elderly; racial and ethnic minorities; sexual and gender minorities; and rural residents into studies and takes steps to enhance participation of these groups; Enhances patient and provider access to treatment and imaging trials conducted under the National Clinical Trials Network (NCTN); Integrates cancer disparities research within the community network. NCORP consists of three components each with its own FOA: NCORP Research Bases; NCORP Community Sites (covered by this FOA); and NCORP Minority/Underserved Community Sites. The NCORP Community Sites will accrue diverse patients/participants to NCI-approved, cancer control, prevention, and care delivery research studies designed by NCI's NCORP Research Bases as well as treatment trials within the National Clinical Trials Network Groups (NCTN).
Funding Opportunity RFA-CA-18-017 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits applications from institutions/organizations to participate as "Minority/Underserved Community Sites" for the National Cancer Institute (NCI)-supported Community Oncology Research Program (NCORP). NCORP is a community-based research network that: Designs and conducts clinical trials and other human subject studies for adults and children in cancer control, prevention, screening, and care delivery, as well as quality-of-life studies embedded within treatment trials; Incorporates the needs of diverse populations such as, adolescents and young adults (AYAs), and the elderly; racial and ethnic minorities; sexual and gender minorities; and rural residents into studies and takes steps to enhance participation of these groups; Enhances patient and provider access to treatment and imaging trials conducted under the National Clinical Trials Network (NCTN); Integrates cancer disparities research within the community network. NCORP consists of three components each with its own FOA: NCORP Research Bases; NCORP Community Sites; and NCORP Minority/Underserved Community Sites (covered by this FOA). The NCORP Minority/Underserved Community Sites will accrue diverse patients/participants to NCI-approved, cancer control, prevention, and care delivery research studies designed by NCI's NCORP Research Bases as well as treatment trials within the National Clinical Trials Network Groups (NCTN).
Notice NOT-NS-18-071 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-RM-18-014 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support large animal Testing Centers to evaluate in vivo genome editing technologies developed by other investigators in the Somatic Cell Genome Editing Program (SCGE). Testing Centers will use either pigs or non-human primates, including wild-type animals, as well as reporter animals developed by RFA-RM-18-013. The Testing Centers will work collaboratively with investigators funded under RM-18-016 and RFA-RM-18-017 to assess efficacy and safety of in vivo genome editing and delivery technologies. Centers will breed, archive and maintain cohorts of well characterized and genotyped large animals, establish methods and protocols for the evaluation of the delivery systems and editing tools, conduct testing and provide results to the Dissemination and Coordination Center of the SCGE. Such activities will accelerate the translation of genome editing technologies into treatments for human diseases.
Funding Opportunity PAR-18-827 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is issued by the Food and Drug Administration (FDA), Center for Veterinary Medicine (CVM), and solicits Research Project (R01) grant applications from institutions or organizations that propose to develop, or support the development of new animal drugs intended for minor use in major species or for use in minor species.
Funding Opportunity RFA-DK-18-009 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) seeks to bring together investigators with complementary expertise in HIV and in gastrointestinal mucosal pathobiology to dissect fundamental processes within the gastrointestinal tract that impact HIV infection, persistence, and comorbidities. This multidisciplinary approach should lead to comprehensive, in-depth mechanistic analyses and advance progress toward alleviating comorbidities that afflict people living with HIV and toward developing a cure.
Funding Opportunity RFA-AI-18-006 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to stimulate the development of new and innovative sustained/extended release drugs and drug delivery systems (DDS) that can achieve extended durations (months to years) of HIV prevention in at-risk individuals. This FOA requires an industry partner, milestones linked to Go/No Go decisions and year 5 funding requires communication with/ pre-IND submission to the FDA.
Notice NOT-EB-18-021 from the NIH Guide for Grants and Contracts
Notice NOT-EB-18-020 from the NIH Guide for Grants and Contracts